Merck's earnings call highlighted substantial confidence in KEYTRUDA's continued success, particularly with upcoming approvals and robust pipeline expansion.  Management emphasized focus on core brands, and indicated  significant investment in R&D for growth.  Positive guidance, even factoring in patent expirations, suggests short-term stability and a long-term positive outlook for the stock.
[1]
